-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, there were reports that Sanofi announced that it would acquire Kadmon Holdings, a US biopharmaceutical company, for US$1.
9 billion (approximately RMB 12.
2 billion)
.
According to the announcement, the acquisition will support Sanofi's strategy to continue to grow its core assets of generic drugs
.
In addition, it is worth mentioning that Kadmon's core product Rezurock (Belumosudil) will also be included in its transplantation drug product portfolio
.
According to data, the only drug listed in the research and development pipeline of Kadmon acquired this time is Rezurock.
This drug is mainly used to treat patients with chronic graft-versus-host disease (cGVHD) aged 12 years and above.
It was approved by the U.
S.
Food and Drug Administration in July this year.
Approved by the FDA, and officially listed on August 30
.
It is understood that transplantation drugs are actually a kind of immunosuppressive agents, mainly used to inhibit the rejection of organ transplantation, so that the transplanted organs can survive well
.
Since the beginning of this year, many pharmaceutical giants have increased the layout of transplant drugs, which is becoming a new focus of pharmaceutical giants
.
Specifically, on August 23, Bristol-Myers Squibb (BMS) announced that the U.
S.
FDA has accepted an application for a supplementary license for the biological product of the acute graft-versus-host disease (aGVHD) drug Orencia (abatacept), which is expected to be the first to prevent acute GVHD.
Therapy
.
It is worth mentioning that as early as December 5, 2019, BMS announced that the FDA granted its Orencia (abatacept) breakthrough therapy designation for the prevention of moderate to severe acute transplantation of hematopoietic stem cell transplantation from unrelated donors.
Host-resistant disease (GvHD)
.
In addition, Novartis and Incyte's JAK inhibitor Jakafi (ruxolitinib) was approved in May this year for the treatment of steroid-refractory acute graft-versus-host disease
.
It is understood that chronic GvHD is a life-threatening disease and a long-term complication of stem cell transplantation, which can affect multiple organs.
About half of patients receiving first-line steroid treatment will develop steroid refractory/dependence.
.
And ruxolitinib is the first drug to show efficacy in the treatment of steroid-refractory/dependent chronic GvHD in large-scale randomized clinical trials
.
Industry analysts believe that the reason why pharmaceutical companies pay so much attention to transplantation drugs is mainly because the field of cell therapy is developing rapidly, and if a series of immune-related drugs such as transplantation drugs can assist in this field, they will follow the wind.
Caused by opportunity
.
For example, for Sanofi, which is undergoing transformation, this will be a new opportunity
.
According to the author's understanding, in recent years, as competition in the pharmaceutical market has intensified, Sanofi has been vigorously looking for new development directions
.
In addition to transplantation drugs, Sanofi also announced the acquisition of US biotechnology company Translate Bio for US$3.
2 billion (approximately RMB 20.
732 billion) as early as a month ago to compensate for its failure to seize opportunities during the epidemic.
Regret to devote all efforts to the research and development of mRNA field
.
However, it should be noted that although a large number of powerful pharmaceutical companies are increasing the deployment of transplant drugs, it will take some time for these bets to be reaped in the future, meet market expectations, and become a real boost for a new generation of cell therapies.
To prove
.
9 billion (approximately RMB 12.
2 billion)
.
According to the announcement, the acquisition will support Sanofi's strategy to continue to grow its core assets of generic drugs
.
In addition, it is worth mentioning that Kadmon's core product Rezurock (Belumosudil) will also be included in its transplantation drug product portfolio
.
According to data, the only drug listed in the research and development pipeline of Kadmon acquired this time is Rezurock.
This drug is mainly used to treat patients with chronic graft-versus-host disease (cGVHD) aged 12 years and above.
It was approved by the U.
S.
Food and Drug Administration in July this year.
Approved by the FDA, and officially listed on August 30
.
It is understood that transplantation drugs are actually a kind of immunosuppressive agents, mainly used to inhibit the rejection of organ transplantation, so that the transplanted organs can survive well
.
Since the beginning of this year, many pharmaceutical giants have increased the layout of transplant drugs, which is becoming a new focus of pharmaceutical giants
.
Specifically, on August 23, Bristol-Myers Squibb (BMS) announced that the U.
S.
FDA has accepted an application for a supplementary license for the biological product of the acute graft-versus-host disease (aGVHD) drug Orencia (abatacept), which is expected to be the first to prevent acute GVHD.
Therapy
.
It is worth mentioning that as early as December 5, 2019, BMS announced that the FDA granted its Orencia (abatacept) breakthrough therapy designation for the prevention of moderate to severe acute transplantation of hematopoietic stem cell transplantation from unrelated donors.
Host-resistant disease (GvHD)
.
In addition, Novartis and Incyte's JAK inhibitor Jakafi (ruxolitinib) was approved in May this year for the treatment of steroid-refractory acute graft-versus-host disease
.
It is understood that chronic GvHD is a life-threatening disease and a long-term complication of stem cell transplantation, which can affect multiple organs.
About half of patients receiving first-line steroid treatment will develop steroid refractory/dependence.
.
And ruxolitinib is the first drug to show efficacy in the treatment of steroid-refractory/dependent chronic GvHD in large-scale randomized clinical trials
.
Industry analysts believe that the reason why pharmaceutical companies pay so much attention to transplantation drugs is mainly because the field of cell therapy is developing rapidly, and if a series of immune-related drugs such as transplantation drugs can assist in this field, they will follow the wind.
Caused by opportunity
.
For example, for Sanofi, which is undergoing transformation, this will be a new opportunity
.
According to the author's understanding, in recent years, as competition in the pharmaceutical market has intensified, Sanofi has been vigorously looking for new development directions
.
In addition to transplantation drugs, Sanofi also announced the acquisition of US biotechnology company Translate Bio for US$3.
2 billion (approximately RMB 20.
732 billion) as early as a month ago to compensate for its failure to seize opportunities during the epidemic.
Regret to devote all efforts to the research and development of mRNA field
.
However, it should be noted that although a large number of powerful pharmaceutical companies are increasing the deployment of transplant drugs, it will take some time for these bets to be reaped in the future, meet market expectations, and become a real boost for a new generation of cell therapies.
To prove
.
